Idorsia
Established: 2017
Country: Switzerland
Region: Allschwil
Investors: Actelion
The sale of Actelion – one of Europe’s most successful biotechs – to Johnson & Johnson in 2017 was the catalyst for the creation of Idorsia, a specialised biotech group focused on the discovery of small molecule treatments for a wide range of common conditions and rare diseases – from insomnia to Fabry disease, a genetic condition that leads to the build-up of fat and raises the risk of heart attack.
Basel, Switzerland-based Idorsia raised over $1 billion in new funding in its IPO to help pursue its pipeline of early-stage treatments, giving it a valuation in excess of $1.5 billion1. The company markets its daridorexant compound for insomnia in the US under the QUVIVIQ label, and aneurysm-related treatment clazosentan as PIVLAZ in Japan.
Idorsia - Reaching Out for More (Video – 02:37)
$1.5bn+
valuation at 2017 spin-out IPO
CHF1.9bn
raised in IPO
1,200
employees in 2022, up from 650 in 2017
Key achievements
Approval and marketing of insomnia medicine QUVIVIQ in the US, and aneurysm-related treatment PIVLAZ in Japan
Strategic partnerships including Johnson & Johnson and its subsidiary Janssen Biotech
Valued at over $1.5bn in 2017 spin-out IPO
Funding history
Raised CHF1.19bn in IPO2
Employment impact
Over 1,200 employees in 2022, up from 650 in 20173
Find out more
1. https://www.cbinsights.com/company/idorsia/financials
2. https://invivo.pharmaintelligence.informa.com/Deals/201730387
3. https://www.idorsia.com/about-idorsia/idorsia-today/index
Investors
